Anti-Classical Swine Fever Serum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions, designated model ACSF-S-VET-01, is a purified porcine hyperimmune serum fraction standardized for homologous classical swine fever virus (CSFV) neutralization activity. The lyophilized immunoglobulin concentrate is released with a total protein content of 80–120 mg/g and a virus neutralization titre not less than 1:512 against CSFV Alfort/187 in a constant-virus decreasing-serum neutralization assay. The drug substance is intended solely for downstream formulation by licensed veterinary pharmaceutical manufacturers; it is not presented as a ready-to-use finished veterinary medicinal product.

Unlike a live attenuated C-strain CSFV vaccine seed, the API contains no replication-competent virus and cannot induce an active immune response. Its function is passive seroneutralization of free CSFV. After intramuscular or subcutaneous injection, neutralizing immunoglobulin reaches systemic circulation; after oral administration in neonatal piglets, the main antiviral effect is local neutralization within the oropharyngeal and gastrointestinal lumen, provided the gut remains permissive to macromolecule uptake or the intended outcome is limited to mucosal surface protection.

Where Does a Hyperimmune Serum API Diverge from Inactivated or Recombinant CSFV Antigens?

The operational divergence is determined by the active molecule and the absence of an antigenic payload. A modified live virus vaccine delivers an attenuated CSFV isolate, generally C-strain or Thiverval, which replicates in the host and stimulates active seroconversion over 7–14 days. An E2 subunit vaccine presents a single surface glycoprotein and supports DIVA serology. By contrast, the serum API supplies pre-formed polyclonal IgG, and minor IgM and IgA fractions, directed against multiple structural determinants including E2 and Erns. Consequently, systemic neutralization after parenteral injection may be reached within 12–24 h, while the protective window is governed by immunoglobulin catabolic half-life in swine, commonly 10–21 days. The product is not a replacement for routine active immunization and must not be administered concurrently with modified-live CSFV vaccines because passive antibody binds the vaccine virus and suppresses the desired immune response; a minimum interval of 21 days is required between serum administration and live vaccination.

Release Specification Envelope for the ACSF-S-VET-01 Concentrate

The neutralization titre is expressed as the reciprocal of the highest dilution producing 50% inhibition of CSFV-induced cytopathic effect in PK-15 cell culture. Because inter-laboratory variation in CSFV neutralization tests can reach 0.5 log10, a working reference serum calibrated against WOAH Terrestrial Manual Chapter 3.8.3 is run in every plate. Cross-neutralization of CSFV genotype 1.1 Alfort/187 and genotype 2.1 reference strains has been observed for polyclonal porcine sera. Where circulating field isolates are genotype 2.3 or other variants, a supplemental neutralization assay against the field strain is recommended because neutralizing titre against a variant cannot be inferred solely from the reference strain.

Donor pigs used for hyperimmunization are derived from a closed, specific pathogen-free herd and are tested free of CSFV, African swine fever virus, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and foot-and-mouth disease virus by validated PCR and serology. Enveloped adventitious viruses are reduced by solvent-detergent treatment with tri-n-butyl phosphate and polysorbate 80, followed by protein G affinity purification and nanofiltration through a 20 nm virus-retentive membrane. Non-enveloped adventitious agents are controlled through donor screening and process barrier design rather than by the solvent-detergent step. These measures distinguish a veterinary active pharmaceutical ingredient from low-purity hyperimmune serum distributed without defined viral reduction data.

Formulation stress studies on pilot-scale equipment have shown that IgG activity is retained more reliably when the lyophilized API is kept below its glass transition temperature than when it is exposed to residual moisture above 3.0% w/w during storage. Batch-to-batch variance in a production-scale lyophilizer is controlled by monitoring product temperature, not shelf temperature; the collapse threshold for a sorbitol-containing matrix is approximately -25°C. A conservative ramp rate of 0.5°C/min and a primary drying chamber pressure of 50–100 mTorr are applied to avoid microcollapse and unacceptable reconstitution time.

For tablet and capsule intermediates, direct compression is preferred over wet granulation because added water can plasticize the amorphous trehalose matrix and reduce neutralizing titre by more than 0.3 log10 in stability trials. Tablets are compressed on a rotary press with 10.0 mm round tooling at 80–120 MPa, yielding hardness of 60–90 N and friability below 1.0% per USP <1216>. Enteric coating with Eudragit L 100-55 at 8–12% w/w weight gain resists gastric pepsin and low pH; release is confirmed by USP <711> dissolution using 0.1 M HCl for 2 h followed by phosphate buffer pH 6.8.

Capsule filling is performed at ≤25% RH to avoid moisture uptake and cross-linking; hydroxypropyl methylcellulose capsules are specified over gelatin because of lower equilibrium moisture. Fill mass is adjusted to deliver not less than the neutralization-activity equivalent of 1.0 mL of reconstituted serum per capsule.

Feed premix and granule forms are prepared by adsorbing the reconstituted concentrate onto low-moisture lactose or maltodextrin carriers in a horizontal ploughshare mixer, followed by low-shear granulation with polyvinylpyrrolidone K30 as binder. Inlet air temperature during fluid-bed drying is limited to ≤45°C, product temperature to ≤35°C, and final granule moisture to 2.0–4.0% w/w. Homogeneity of the premix is assessed by neutralizing titre in 10 random samples with relative standard deviation below 5.0%. Steam pelleting above 70°C is not permitted because heat-induced aggregate formation removes Fab-region antigen-binding activity.

For parenteral solutions, the lyophilized powder is reconstituted in Water for Injection to a total protein concentration of 40–80 mg/mL, then filtered through a 0.22 µm low-protein-binding polyethersulfone membrane in a Grade A aseptic filling line. Osmolality is adjusted to 280–320 mOsm/kg with glycine or sorbitol; hypertonic sodium chloride formulations are not used because high ionic strength accelerates IgG aggregation. Thimerosal and benzalkonium chloride are incompatible with the immunoglobulin fraction, and multi-dose vials are acceptable only if preservative efficacy testing per USP <51> is validated without loss of neutralizing titre.

Oral solutions and drinking-water formulations are buffered to pH 6.8–7.4 and protected from light. Residual free chlorine above 0.5 ppm oxidizes methionine residues and reduces potency; sodium thiosulfate at 0.01–0.05% w/v is incorporated where necessary. Prolonged contact with copper, iron, or zinc plumbing is avoided because transition-metal ions catalyse fragmentation of immunoglobulin hinge-region disulfide bridges.

If the API Is Formulated as a Premix for Neonatal Piglet Gut-Localized Protection

For piglets older than 36–48 h after colostrum intake, intestinal macromolecule absorption is substantially reduced, and orally delivered porcine IgG is not expected to enter systemic circulation in therapeutically relevant quantities. The antiviral action of oral tablets, capsules, powders, granules, premix, and solutions in this age window is therefore confined to luminal and mucosal contact surfaces, not systemic passive immunity. Published data for this specific configuration is limited; the appropriate dose and duration for each oral dosage form should be confirmed by virus challenge and seroneutralization kinetic studies under target farm conditions. Injection of the same API remains the route of choice when systemic neutralization is required in viremic animals.

What Separates a Porcine Hyperimmune Serum API from Avian IgY and Monoclonal Antibody Preparations?

Hyperimmune avian IgY is produced in egg yolk and does not activate mammalian complement efficiently; it is generally restricted to oral use because parenteral administration can provoke anti-species immune responses. The porcine serum IgG in ACSF-S-VET-01 is homologous with the target species, carries porcine Fc domains compatible with porcine FcRn and effector functions, and may be used in injectable formulations after appropriate safety testing. Compared with a monoclonal anti-E2 antibody, the polyclonal fraction has broader epitope coverage and a higher likelihood of cross-neutralizing heterologous CSFV field isolates, but its specific activity per milligram of total IgG is lower. The major limitation of all passive-antibody products is the absence of immunological memory; protection lasts only until catabolic clearance of the administered immunoglobulin.

In multi-product veterinary manufacturing facilities, cleaning validation for the API is based on residual porcine IgG by ELISA after defined cleaning cycles; an acceptance criterion of not more than 10 ng/cm² is applied to shared product-contact surfaces. Proteinaceous residues must be removed with alkaline detergent at 50–60°C before steam-in-place cycles, because direct steam exposure above 121°C bakes immunoglobulin films onto stainless steel and reduces cleanability. The lyophilized API is stored at 2–8°C in Type I borosilicate glass vials sealed under nitrogen headspace with bromobutyl stoppers; short-term stability at 25°C for 14 days is acceptable when protected from light. The product is not compatible with glutaraldehyde, formaldehyde, or amine-based buffers because carbonyl and amine reactions can cross-link the immunoglobulin fraction and destroy antigen-binding activity.